TY - JOUR
T1 - Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles for the co-delivery of dox/cpt-peg for targeting hepg2 cells
AU - Martínez-Edo, Gabriel
AU - Fornaguera, Cristina
AU - Borrós, Salvador
AU - Sánchez-García, David
N1 - Funding Information:
G.M.-E. is grateful to IQS for the financial support. We would like to thank Generalitat de Catalunya for the consolidated Research Group Grant 2017SGR 01559 to GEMAT. Part of this work has been also supported by a grant from the Spanish Ministerio de Ciencia, Inovación y Universidades through the Grant: RTI2018-094734-B-C22.
Funding Information:
Funding: G.M.-E. is grateful to IQS for the financial support. We would like to thank Generalitat de Catalunya for the consolidated Research Group Grant 2017SGR 01559 to GEMAT. Part of this work has been also supported by a grant from the Spanish Ministerio de Ciencia, Inovación y Universidades through the Grant: RTI2018-094734-B-C22.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/11
Y1 - 2020/11
N2 - A pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX.
AB - A pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX.
KW - Anticancer drugs
KW - Camptothecin
KW - Combination therapy
KW - Doxorubicin
KW - Dual release
KW - Mesoporous silica nanoparticles
KW - Targeting systems
UR - http://www.scopus.com/inward/record.url?scp=85096017000&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000593799600001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.3390/pharmaceutics12111048
DO - 10.3390/pharmaceutics12111048
M3 - Article
C2 - 33147860
AN - SCOPUS:85096017000
SN - 1999-4923
VL - 12
SP - 1
EP - 17
JO - Pharmaceutics
JF - Pharmaceutics
IS - 11
M1 - 1048
ER -